Review
Recent development in induced pluripotent stem (iPS) cell technology provides powerful tools to generate patient-specific stem cells for both therapeutic and research purposes. Derivation of mouse iPS cells was first reported in 2006 by the Yamanaka group [1] . In this groundbreaking study, mouse embryonic fibroblasts and tail tip fibroblasts were transduced with combinations of retroviruses expressing candidate genes that are preferentially expressed in, or believed to be essential to the growth of, embryonic stem cells (ESCs). Using an elegant (albeit imperfect as the first version) genetic screen, they found that a few clones displayed mouse ESC morphology and proliferation capacity when cultured under mouse ESC culture conditions. These iPS cells could form teratomas that contained tissues of all three germ layers in vivo. They further narrowed down the list of genes that are required for efficient direct reprogramming of both embryonic and adult mouse fibroblasts to a combination of four: Oct4, Sox2, Klf4 and c-Myc [1] . Later, several groups used the same four factors and improved reprogramming techniques to demonstrate that successfully reprogrammed mouse iPS cell lines are indeed pluripotent and germline transmission competent, similar to mouse ESCs [2, 3] .
Less than 18 months after the first report in mice [1] , several groups independently reported the reprogramming of human cells using either the same set of factors as Yamanaka or with small modifications or additions [4] [5] [6] [7] [8] . Although the addition of NANOG, LIN28 and SV40 large T antigen further enhanced the pace and efficiency of reprogramming [5, 8] , it later became evident that the four Yamanaka factors are sufficient for reprogramming human fetal and adult fibroblasts. The iPS cell lines generated from human fibroblasts exhibit characteristics of human ESCs and can be expanded extensively under human ESC culture conditions. They express a set of cell surface markers such as TRA-1-60/TRA-1-81, and SSEA3/SSEA4, which are expressed in undifferentiated human ESCs and diminished after differentiation. The endogenous gene expression of transcriptional regulators that are important to human ESCs, such as NANOG and OCT4, is also upregulated in iPS cells. The successfully reprogrammed human iPS cells are capable of differentiating into various cell types by in vitro and in vivo assays, demonstrating their pluripotency. Subsequently, several groups have demonstrated that human iPS cells can be generated with a reduced number of factors, with the most success coming from reprogramming neural stem cells that already express SOX2, KLF4 and c-MYC [9] [10] [11] [12] . Ultimately, human iPS cells need to be generated without permanent genomic alteration. Although it has been achieved using EBV OriP/EBNA1-based episomal plasmid transient transfection and by delivery of recombinant transcription factors to newborn dermal Human induced pluripotent stem (iPS) cells have been generated from various cell types including blood cells, and offer certain advantages as a starting population for reprogramming postnatal somatic cells. Unlike adult stem cells, iPS cells can proliferate limitlessly in culture while retaining their potential to differentiate into any cell type, including hematopoietic lineages. Derivation of patient-specific iPS cells, in combination with improved hematopoietic differentiation protocols, provides an alternative to generate histocompatible stem cells for bone marrow transplantation. In addition, the ability to reprogram blood cells and redifferentiate iPS cells back to hematopoietic lineages provides opportunities to establish novel models for acquired and inherited blood diseases. This article will summarize recent progress in human iPS cells derived from blood cells and hematopoietic differentiation from iPS cells. Advantages of blood as a source for reprogramming and applications in regenerative medicine will be discussed.
future science group Review Ye & Cheng fibroblasts, the efficiency of integration-free reprogramming of fibroblasts is extremely low [13, 14] . Nevertheless, these studies demonstrated the principle that genomic integration of retroviruses is not essential for generating iPS cells. As an intermediate approach, piggyBac DNA transposition has been shown to be effective in the generation of iPS cell lines from mouse and human embryonic fibroblasts [15, 16] . Transient piggyBac transposase expression can catalyze both integration and scar-free excision of the transposon vector expressing the reprogramming genes. This unique feature of piggyBac DNA transposition has been used to generate mouse iPS cells where the integrated transgenes were completely removed [15, 16] . It has been shown that the same single piggyBac transposon vector expressing five transgenes [15] is able to reprogram human adult mesenchymal cells, including those from an adult patient with sickle cell disease [17] . The reprogramming efficiency by the piggyBac transposon vector is approximately 50-fold lower than that by four retroviral vectors. However, the reduction of reprogramming efficiency by the piggyBac transposon plasmid can be largely compensated by adding a small molecule such as butyrate that enhances the piggyBac-mediated iPS cell derivation by approximately 25-fold [17] . It remains to be determined how efficient the integrated piggyBac vector could be excised by the re-expression of piggyBac transposase in fully reprogrammed human iPS cells. With the increasing knowledge of reprogramming mechanisms and the continuing efforts on screening small molecules that can replace or enhance the effects of transcription factors, it is anticipated that efficient protocols for generating human iPS cells from adult somatic cells without genomic alteration can be achieved in the near future.
Blood cells as a source for reprogramming
The majority of earlier experiments for reprogramming adult human cells have been done using fibroblastic cells derived from skin biopsies (typically two <5 mm 3 full-thickness skin tissues) or from marrow aspirates ( Figure 1A ) [4] [5] [6] [7] [8] . However, it is highly desirable to generate iPS cells from easily accessible sources, such as peripheral blood, without an invasive procedure ( Figure 1B) . Generation of iPS cells from blood cells offer several advantages over other cell types. It is more convenient and less invasive to obtain blood than some other types of tissues, such as skin. Unlike skin fibroblasts and keratino cytes, which require several weeks to establish primary cell culture from biopsy, mononuclear hematopoietic cells isolated from blood can be utilized for reprogramming almost immediately, shortening the total time of iPS cell line establishment. The blood cell reprogramming process can also be applied to the large collections of umbilical cord blood (CB) that are stored in many CB banks. The diversified genetic backgrounds in CB banking, as well as the possibility that the neonatal CB cells are less likely to accumulate genetic mutations than some other adult tissues, make CB cells an attractive source for establishing iPS cell banks with a broad coverage of various human leukocyte antigen haplotypes. This provides the opportunity to generate a bank of histocompatible iPS cell lines for many individuals who need a matched and readily available allogeneic cell source sufficient for cell therapy.
Reprogramming of hematopoietic mononuclear cells, such as B cells, was first reported in the mouse [18] . Hanna et al. utilized a 'secondary reprogramming system,' in which the mouse embryonic fibroblasts were first reprogrammed to pluripotency using lentiviruses expressing Oct4, Sox2, Klf4 and c-Myc in a doxycyclin-dependent fashion. After chimeric animals were generated following injection of these iPS cells into blastocysts, B cells representing various developmental stages were isolated and subjected to reprogramming by doxycyclin-induced reactivation of the four reprogrammed genes. They demonstrated in this system that the cells committed to B lineage (indicated by genomic DNA rearrangement at the immunoglobin loci) can be reprogrammed by this approach, although the reprogramming of more mature differentiated B cells may require additional factors (e.g., C/EBP-a) [18] . Nonetheless, it provided the proof-of-principle that differentiated cells, such as mouse B cells, can be directed to pluripotency through the overexpression of defined transcription factors.
Several laboratories subsequently reported the reprogramming of human blood cells [12, [19] [20] [21] [22] . Loh et al. reprogrammed CD34 + hematopoietic stem/progenitor cells (HSPCs) isolated from the peripheral blood of a healthy donor after granulocyte colony-stimulating factor mobilization, using the retroviruses expressing the four Yamanaka factors [20] . It has been subsequently reported that iPS cells were generated from CB and adult CD34 + or CD133 + HSPCs (~50% of CD34 + cells express CD133) [12, [20] [21] [22] as well as from CB-derived endothelial cells [19] . We also assessed the feasibility of reprogramming adult bone marrow (BM) CD34 + cells that have been future science group
Potential of human iPS cells derived from blood & other postnatal cell types Review frozen for over 9 years. After retroviral transduction and further culture under human ESC culture conditions, iPS-like colonies emerged from blood and BM CD34 + cells. Upon further expansion, the iPS clones displayed typical human ESC morphology and pluripotency [21] . These reports of human blood cell-derived iPS cells used HSPCs. HSPCs that can be enriched by CD34 or CD133 expression have the ability to proliferate and expand transiently in culture. Compared with some other lineage-committed cells (e.g., T or B cells), they can be transduced by retroviruses more efficiently, although the transduction efficiency may not be as high as fibroblastic cells. It is also conceivable that the epigenetic states of these cells are closer to a pluripotent state than other more differentiated lineages. These characteristics make HSPCs a more preferred source for reprogramming of adult cells. Indeed, all of these reports showed that HSPCs can be reprogrammed as efficiently as fibroblast cells. Giorgetti et al. have demonstrated that CB CD133 + cells can be reprogrammed even with a reduced number of factors (OCT4 and SOX2) [12] . In one study, we were able to generate human iPS cells from CB and adult blood CD34 + cells with the piggyBac DNA transposon vector that we previously used to reprogram human adult mesenchymal cells [17] . Currently, it is being tested if episomal plasmid vectors can efficiently reprogram human CD34 + HSPCs that appear more conducive to derive iPS cells than dermal fibroblasts.
In a separate study with mouse hematopoietic lineages, it has also been shown that HSPCs have a higher reprogramming efficiency than the more differentiated lineages, owing to either the intrinsic epigenetic differences or the fact that HSPCs can be better maintained and expanded in tissue culture conditions [23] . Although terminally differentiated blood cells have been reprogrammed back to iPS cells in the mouse secondary reprogramming system, it has not been demonstrated that more differentiated human blood cells can be reprogrammed at a reasonable efficiency. Similar to what was observed in fibroblast cell reprogramming [24] [25] [26] [27] [28] [29] [30] , knocking down p53 significantly enhanced the efficiency of generating iPS cells from CD34 + CB cells [22] , suggesting that the mechanisms underlying reprogramming processes from fibroblasts and blood cells are fundamentally similar. Improved gene delivery and small molecules that facilitate the reprogramming process are likely to be key in enhancing the efficiency of generating iPS cells from more differentiated or unfractionated + cells in the peripheral blood of healthy individuals is much lower than CB and BM. Mobilization (e.g., by granulocyte colony-stimulating factor treatment for 3-5 days) of CD34 + cells to peripheral blood is often used to enrich and obtain more HSCs and HSPCs [32] . In addition to the rarity of HSCs, HSC transplantation and research have been limited by the lack of a reproducible protocol to expand human HSCs in culture. However, we are still optimistic that someone will find a solution to achieve this elusive goal, aided by the advent of better understanding of stem cell biology. Ever since human ESC lines were established, it has been anticipated that pluripotent stem cells that can be expanded in culture indefinitely followed by differentiation into hematopoietic cells may serve as unlimited sources for BMT and blood transfusion purposes. The derivation of human iPS cells makes it possible to create patient-specific stem cell lines. This technology, in combination with further optimized hematopoietic differentiation methods, should provide a vital alternative way to store and amplify histocompatible blood stem cells for BMT purposes.
Human ESCs have been instrumental in studying human embryonic development, including blood formation [34, 35] . Various hemato poietic cell types, including red blood cells [36] [37] [38] [39] [40] [41] , dendritic cells [42] , monocytes [43] , megakaryocytes [44] and lymphoid cells [45] have been reported to be generated from human ESCs and have been recently reviewed [46] . [47] . These iPS cells were then differentiated to hematopoietic cells using a HoxB4 expressing EB formation protocol that has been successful in mouse ESC differentiation. It was shown that the hematopoietic progenitor cells generated from this process can engraft into recipient mice, similar to what is reported previously using mouse ESCs [47, 48] . Although the human system is vastly different from the mouse in many ways, preliminary studies from our laboratory and others have shown that human iPS cells can be directed to hematopoietic lineages in a fashion similar to human ESC differentiation [6,21,49-52].
Park et al. first demonstrated the generation of hematopoietic colony-forming cells from iPS cells that were originally generated from skin fibroblast cells [6] . Using the serum-containing EB formation protocol, these authors also demonstrated in a separate study that BMP4 supports mesoderm induction and hematopoietic development from human fibroblast-derived iPS cells similar to human ESCs [49] . Choi et al. used the OP9 (mouse) stromal co-culture system to study hematopoietic and endothelial differentiation of multiple human iPS cell lines that were derived using slightly different reprogramming cocktails (OCT4, SOX2, NANOG and LIN28) [52] . Their results showed that hematopoietic cells can be generated from all of the iPS cell lines tested, although efficiency varied among iPS cell lines. The hematopoietic potential of the iPS cell lines derived from fetal and neonatal fibroblasts by the integrating viral vectors is similar to that of human ESCs as a group [48] . We assessed the possibility to differentiate iPS cells in serum-free, feeder-free conditions using a chemically defined medium. By sequentially treating iPS-derived future science group
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EBs with growth factors BMP4, bFGF, VEGF and SCF, a significant percentage of cells expressing hematopoietic progenitor markers CD34 and CD45 can be obtained. These cells can form both myeloid and erythroid colonies in methylcellulose assays [21] . More recently, Grigoriadis et al. reported a step-wise differentiation process in which hematopoietic precursors were generated from human ES and iPS cells following EB formation [50] .
These studies have demonstrated in principle that hematopoietic cells can be generated from iPS cells, although no studies have demonstrated the ability of HSCs derived from human ES or iPS cells to reconstitute an immune-deficient mouse to any meaningful extent. The iPS techno logy, however, is still in its infancy and many questions remain. One key issue that needs to be addressed is the similarity and differences between iPS cells from different origins as well as between iPS cells and ESCs. Genome-wide transcriptome analyses indicated that human iPS cells display distinct gene expression patterns compared with blastocyst-derived human ESCs, and that human fi broblast-derived iPS cells conuman fibroblast-derived iPS cells continue expressing some fibroblast-restricted genes that are inactive in neural stem cell-derived iPS cells and ESCs [53, 54] . DNA methylation studies of multiple lines of human ES and iPS cells also showed distinct epigenetic features among these cell lines [55, 56] . These distinct epigenetic features may be the result of incomplete reprogramming. It is therefore important to determine whether iPS cells derived from different origins possess epigenetic memories that are inherited from the starting cell types and, more importantly, how much would the origin of iPS cells affect differentiation propensity. We hypothesize that such epigenetic memories do exist and that bloodderived iPS cells may offer advantages for hematopoietic differentiation. Derivation of iPS cells from fibroblast cells as well as blood cells of the same individual would provide an ideal system to test the hypothesis. The information obtained from this type of study will not only improve our understanding of iPS biology but will also provide a foundation to improve current iPS cell differentiation protocols for disease modeling and cell therapy. Once a condition to expand human HSCs in culture is developed, we may be able to reprogram mature blood cells back to HSCs (dedifferentiation) or to reprogram readily available mesenchymal cells to HSCs (transdifferentiation) without the need to go all the way back to a pluripotent state of iPS cells/ESCs.
Human iPS cells & blood disease modeling
In addition to the potential cell replacement therapy, another interesting and more eminent application of iPS cells would be for disease modeling. Patient-specific iPS cells that carry diseasespecific genetic information would be invaluable tools for delineating pathogenesis and for drug screening. For this reason, several patient-specific iPS cell lines have been reported shortly after the initial reports of human cell reprogramming [57] [58] [59] [60] [61] [62] . We have derived human iPS cell lines containing the homozygous HbS mutation using fibroblasts, which could be used to develop a novel research model for the treatment of sickle cell disease [8] . However, for many other blood diseases, the underlying mutation is acquired and restricted to hematopoietic cells. Therefore, fibroblast-or keratinocyte-derived iPS cells would not contain the disease-related genomic abnormalities (Figure 2 ). Myeloproliferatve disorders (MPDs) are such a group of diseases.
The classic Philadelphia-chromosome (BCR/ABL)-negative MPDs are a heterogeneous group of diseases characterized by increased proliferation of the erythroid, megakaryocyte or granulocyte lineages [63, 64] . This group of diseases includes polycythemia vera (PV), essential thrombocytosis and primary myelofibrosis [65] . Unlike chronic myeloid leukemia, in which the Philadelphia chromosome or BCR/ABL's role in pathogenesis had been well studied, the underlying genetic defects in other MPDs were not well defined until the discovery of JAK2-V617F mutations in 2005 [66] [67] [68] [69] [70] [71] . It has been reported that this mutation occurs at a frequency close to 95% in PV, 50% in essential thrombocytosis and 58% in primary myelofibrosis [66] [67] [68] [69] [70] [71] [72] [73] . However, as with many other significant discoveries, it has raised more questions than it has answered. One of the top questions is why the same mutation attributes to three apparently different phenotypes in patients. There have been various hypotheses, such as that gene dosages (e.g., heterozygous vs homozygous V617F) may affect the stem/progenitor cell behavior [74] [75] [76] [77] . In addition to JAK2-V617F, there are other types of mutations that also contribute to the MPD pathogenesis [78] [79] [80] [81] [82] [83] [84] [85] . Related to the latter hypothesis are recent reports that support the idea that there are also pre-JAK2 lesion(s) in the patients that predispose them to the acquisition of a JAK2-V617F mutation at the multipotent stem/progenitor cell level [86] [87] [88] . Identifying this pre-JAK2 mutation(s) would have tremendous implications in MPD prevention and future science group Review Ye & Cheng treatment. Mouse models that overexpress JAK2-V617F mutation by transgenic or adoptive BMT approaches reproduced some phenotypes seen in chronic MPDs [76, 77, [89] [90] [91] . These animal models are likely to be useful for testing anti-JAK2 drugs. However, it is unlikely that the current animal models are adequate for the identification of pre-JAK2-V617F lesions since overexpression of the JAK2-V617F mutant results in an acute MPD disease but lacks diseased clones. Similarly, overexpressing the JAK2-V617F mutated allele in human CD34
+ cells would unlikely reveal the nature of pre-JAK2 lesions and their relationship to the JAK2 mutation. New approaches to establish a prospective model to study chronic MPDs at a clonal level are needed to understand the underlying pathophysiology and to develop an effective treatment. As the first step of modeling MPDs using pluripotent stem cells, we derived multiple iPS cell lines from the peripheral blood CD34 + cells of two MPD patients [21] . These patient-specific cell lines fulfill all the requirements for pluripotency by both in vitro and in vivo assays. They also carry the JAK2-V617F mutation, as the primary hematopoietic progenitor cells from the corresponding patients. Using the serum-free hematopoietic differentiation protocol, these iPS cell lines have been differentiated to CD34 + CD45 + hematopoietic progenitor cells. Most importantly, the HSPCs generated from the PV patient-specific iPS cells showed enhanced erythropoiesis compared with healthy controls when they were placed into erythroid differentiation conditions, recapitulating the major clinical feature of PV [21] . It is anticipated that other blood diseases, such as paroxysmal nocturnal hemoglobinuria, which also has acquired somatic mutations in the PIG-A gene, can be modeled by this approach. Combined with improved gene targeting technology that enables us to create or correct a genetic mutation in human iPS and ESCs [92] , the iPS approach offers unique opportunities to study the roles of JAK2-V617F and other genetic mutations in acquired and inherited blood disorders.
For modeling other blood diseases affected by germline mutations, the choice of starting cells for reprogramming can be more flexible. However, certain genetic mutations may negatively regulate the reprogramming process and alternative approaches need to be explored. Fanconi anemia (FA) is an example of such an disease. FA is a recessive chromosomal instability disorder caused by mutation(s) in genes in the FA pathway [93] . The major source of mortality in FA is complications associated with BM failure [94] . Mouse models Potential of human iPS cells derived from blood & other postnatal cell types Review with a gene knockout in the FA pathway failed to develop BM failure, although these mice do display sensitivity to DNA crosslinking reagents [95] .
There is a need to create human disease models to study and treat FA. Raya et al. reported the attempt to reprogram skin fibroblast cells from FA patients to generate patient-specific iPS cells [60] . However, all reprogramming attempts from uncomplemented somatic cells failed, presumably caused by the accumulated genomic alterations.
As an alternative approach, the authors were able to generate iPS cells from patient fibroblast cells that had been genetically corrected before reprogramming [60] . These FA iPS cells can give rise to hematopoietic progenitors that are phenotypically normal, providing a cell source for potential cell therapy applications. More recently, Tulpule et al. reported a different approach to create pluripotent stem cells to model FA [96] . Instead of reprogramming patient somatic cells, these authors used lentiviral RNAi technology to knockdown FANCA and FANCD2, two genes in the FA pathway. Reduced hematopoiesis from these modified human ESCs was observed and the reduction can be rescued by FA gene complementation [96] . These two studies provide examples of how to model or treat diseases using a pluripotent stem cell approach when the genetic mutation of interest is detrimental to reprogramming. In addition to generating hematopoietic cells that can recapitulate blood disease features, iPS cells and their hematopoietic progeny will also facilitate the establishment of improved in vivo models for many other diseases, such as Type 1 diabetes and liver cirrhosis, in which the immune system plays important roles in disease progression. Currently, most in vivo models of human diseases involve immunodeficient mice that are suitable for the engraftment of human cells. However, they could not faithfully recapitulate disease progression or recovery in patients with a functional immune system. Although significant improvements are still needed, the technologies for iPS cell generation and hematopoietic differentiation provide the potential of creating humanized xenograft disease models with autologous immune cells and other cell types that are genetically identical.
Conclusion & future perspective
Recent progress in iPS technology has opened up unprecedented opportunities for the development of new strategies to model and treat diseases. The ability to reprogram blood cells and to differentiate iPS cells back to blood cells makes it possible to model blood diseases carrying acquired somatic mutations in hematopoietic systems. The differences between iPS cells generated from different origins are not clear. Future studies on the epigenetic features and differentiation propensities of these different iPS cells will provide valuable information on iPS cell biology. Knowledge obtained from these studies will facilitate the development of safer and more efficient cell therapy. No writing assistance was utilized in the production of this manuscript.
Executive summary

Blood cells as a source for reprogramming
Human blood CD34 + cells can be reprogrammed to pluripotency at compatible efficiencies to fibroblast reprogramming. It is less invasive to obtain blood and easy to prepare blood cells for reprogramming. Cord blood cells represent potential sources for establishing induced pluripotent stem (iPS) cell banks.
Blood cells generated from iPS cells
Several protocols have been established to direct human iPS cells to hematopoietic cell types. Patient-specific iPS cells may provide alternative sources for histocompatible blood stem cells for bone marrow transplantation.
Blood-derived iPS cells may offer advantages for hematopoietic differentiation owing to potential epigenetic memory.
Human iPS cells & blood disease modeling
Acquired blood disorders containing hematopoietic-restricted somatic mutations can be modeled by blood cell-derived iPS cells. Fibroblast or other cell types can be used to derive blood disease-specific iPS cells if the mutation is inherited, such as in sickle cell anemia and Fanconi anemia. Certain genetic abnormalities may interfere with the reprogramming process; alternative approaches need to be explored. The first report of human iPS cell lines generated from blood CD34 + cells after granulocyte colony-stimulating factor mobilization. 21 
